首页 > 最新文献

Journal of Investigational Allergology and Clinical Immunology最新文献

英文 中文
Sex Differences in Baseline Risk Factors for Asthma Between Early Adolescence and Young Adulthood. 青春期早期和青年期哮喘发病率基线风险因素的性别差异。
IF 6.1 3区 医学 Q1 ALLERGY Pub Date : 2024-10-01 Epub Date: 2021-04-15 DOI: 10.18176/jiaci.0763
P Kalm-Stephens, L Nordvall, C Janson, A Malinovschi, K Alving

Background: Several studies have shown sex differences in the prevalence of asthma and an association with age. The aim of the present study was to prospectively investigate the development of asthma, wheeze, rhinitis, and allergic symptoms in adolescence and adulthood. We also aimed to determine whether sex modifies the association between baseline risk factors and incidence of asthma in early adulthood.

Methods: In the Screening Project Asthma in Schools (SPAIS) study, adolescents aged 12-15 years completed a standardized respiratory questionnaire (International Study of Asthma and Allergies in Childhood) and underwent measurements of fractional exhaled nitric oxide (FeNO) and lung function (FEV1) at baseline. Two follow-up assessments with similar questionnaires were performed after 4 and 16 years, with a total of 491 participants in all 3 examinations.

Results: The prevalence of asthma and wheeze were unchanged after 4 years but had increased after 16 years. However, the increase was significant only for females. The prevalence of rhinitis and allergy symptoms increased steadily, albeit with no differences between the sexes. The sex interaction analysis showed that higher FeNO (P=.01) and a family history of asthma (P=.02) increased the risk of incident asthma for males but not for females.

Conclusions: An increased prevalence of respiratory symptoms was seen primarily between late adolescence and young adulthood; the difference was significant for females but not for males. Allergic risk factors in early adolescence for incident asthma in early adulthood were confirmed in males but not in females. Awareness of these sex differences in the development of symptoms and of the associated risk factors is important in clinical practice.

背景:多项研究表明,哮喘发病率存在性别差异,并与年龄有关。本研究旨在前瞻性地调查哮喘、喘息、鼻炎和过敏症状在青春期和成年期之间的发展情况。此外,还要确定性别是否会改变基线风险因素与成年早期哮喘发病率之间的关联:在学校哮喘筛查项目(SPAIS)研究中,12-15 岁的青少年回答了一份标准化呼吸系统问卷(ISAAC),并在基线测量了呼出一氧化氮分数(FeNO)和肺功能(FEV1)。在 4 年和 16 年后进行了两次类似问卷的随访,共有 491 名受试者参加了所有三次检查:结果:哮喘和喘息的发病率在 4 年后没有变化,但在 16 年后有所增加。不过,只有女性的发病率有明显增加。鼻炎和过敏症状的持续增长在性别上没有差异。性别交互分析表明,较高的 FeNO(p = 0.01)和家族哮喘(p = 0.02)会增加男性哮喘发病的风险,但不会增加女性哮喘发病的风险:结论:呼吸道症状发病率的增加主要出现在青春期晚期和青年期,对女性显著,对男性则不显著。青春期早期的过敏性风险因素对成年早期哮喘事件的影响在男性中得到证实,但在女性中却没有得到证实。在临床实践中,认识到症状发展中的这些性别差异以及相关的风险因素非常重要。
{"title":"Sex Differences in Baseline Risk Factors for Asthma Between Early Adolescence and Young Adulthood.","authors":"P Kalm-Stephens, L Nordvall, C Janson, A Malinovschi, K Alving","doi":"10.18176/jiaci.0763","DOIUrl":"10.18176/jiaci.0763","url":null,"abstract":"<p><strong>Background: </strong>Several studies have shown sex differences in the prevalence of asthma and an association with age. The aim of the present study was to prospectively investigate the development of asthma, wheeze, rhinitis, and allergic symptoms in adolescence and adulthood. We also aimed to determine whether sex modifies the association between baseline risk factors and incidence of asthma in early adulthood.</p><p><strong>Methods: </strong>In the Screening Project Asthma in Schools (SPAIS) study, adolescents aged 12-15 years completed a standardized respiratory questionnaire (International Study of Asthma and Allergies in Childhood) and underwent measurements of fractional exhaled nitric oxide (FeNO) and lung function (FEV1) at baseline. Two follow-up assessments with similar questionnaires were performed after 4 and 16 years, with a total of 491 participants in all 3 examinations.</p><p><strong>Results: </strong>The prevalence of asthma and wheeze were unchanged after 4 years but had increased after 16 years. However, the increase was significant only for females. The prevalence of rhinitis and allergy symptoms increased steadily, albeit with no differences between the sexes. The sex interaction analysis showed that higher FeNO (P=.01) and a family history of asthma (P=.02) increased the risk of incident asthma for males but not for females.</p><p><strong>Conclusions: </strong>An increased prevalence of respiratory symptoms was seen primarily between late adolescence and young adulthood; the difference was significant for females but not for males. Allergic risk factors in early adolescence for incident asthma in early adulthood were confirmed in males but not in females. Awareness of these sex differences in the development of symptoms and of the associated risk factors is important in clinical practice.</p>","PeriodicalId":50173,"journal":{"name":"Journal of Investigational Allergology and Clinical Immunology","volume":" ","pages":"21-29"},"PeriodicalIF":6.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10743472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Systemic Corticosteroids in Patients With Bronchial Asthma: A Real-Life Study. 支气管哮喘患者的全身皮质类固醇治疗:一项真实生活研究
IF 6.1 3区 医学 Q1 ALLERGY Pub Date : 2024-10-01 Epub Date: 2021-04-15 DOI: 10.18176/jiaci.0765
J L Izquierdo, C Almonacid, C Campos, D Morena, M Benavent, D González-de-Olano, J M Rodríguez

Objective: The objective of the present study was to determine the use of systemic corticosteroids (SCs) in patients with bronchial asthma using big data analysis.

Methods: We performed an observational, retrospective, noninterventional study based on secondary data captured from free text in the electronic health records. This study was performed based on data from the regional health service of Castille-La Mancha (SESCAM), Spain. We performed the analysis using big data and artificial intelligence via Savana® Manager version 3.0.

Results: During the study period, 103 667 patients were diagnosed with and treated for asthma at different care levels. The search was restricted to patients aged 10 to 90 years (mean age, 43.5 [95%CI, 43.4-43.7] years). Of these, 59.8% were women. SCs were taken for treatment of asthma by 58 745 patients at some point during the study period. These patients were older, with a higher prevalence of hypertension, dyslipidemia, diabetes, obesity, depression, and hiatus hernia. SCs are used frequently in the general population with asthma (31.4% in 2015 and 39.6% in 2019). SCs were prescribed mainly in primary care (59%), allergy (13%), and pulmonology (20%). The frequency of prescription of SCs had a direct impact on the main associated adverse effects.

Conclusion: In clinical practice, SCs are frequently prescribed to patients with asthma, especially in primary care. Use of SCs is associated with a greater number of adverse events. It is necessary to implement measures to reduce prescription of SCs to patients with asthma, especially in primary care.

研究目的本研究的目的是利用大数据分析确定支气管哮喘患者使用全身性皮质类固醇(SC)的情况:我们根据电子健康记录中的自由文本获取的二手数据,开展了一项观察性、回顾性、非干预性研究。这项研究基于西班牙卡斯蒂利亚-拉曼恰地区卫生服务机构(SESCAM)的数据。我们通过 Savana® Manager 3.0 版使用大数据和人工智能进行了分析:在研究期间,共有 103 667 名哮喘患者在不同级别的医疗机构接受了诊断和治疗。搜索对象仅限于 10 至 90 岁的患者(平均年龄为 43.5 [95%CI, 43.4-43.7] 岁)。其中 59.8% 为女性。在研究期间,有 58 745 名患者曾在某段时间服用过 SCs 治疗哮喘。这些患者年龄较大,高血压、血脂异常、糖尿病、肥胖、抑郁和食道裂孔疝的发病率较高。普通哮喘患者经常使用镇静剂(2015 年为 31.4%,2019 年为 39.6%)。开具 SCs 处方的主要是初级保健科(59%)、过敏科(13%)和肺病科(20%)。SCs处方的频率对主要相关不良反应有直接影响:结论:在临床实践中,哮喘患者,尤其是初级医疗机构的哮喘患者经常会被处方SCs。结论:在临床实践中,哮喘患者尤其是基层医疗机构的哮喘患者经常会被处方解痉剂。有必要采取措施减少哮喘患者(尤其是基层医疗机构的哮喘患者)的SCs处方。
{"title":"Systemic Corticosteroids in Patients With Bronchial Asthma: A Real-Life Study.","authors":"J L Izquierdo, C Almonacid, C Campos, D Morena, M Benavent, D González-de-Olano, J M Rodríguez","doi":"10.18176/jiaci.0765","DOIUrl":"10.18176/jiaci.0765","url":null,"abstract":"<p><strong>Objective: </strong>The objective of the present study was to determine the use of systemic corticosteroids (SCs) in patients with bronchial asthma using big data analysis.</p><p><strong>Methods: </strong>We performed an observational, retrospective, noninterventional study based on secondary data captured from free text in the electronic health records. This study was performed based on data from the regional health service of Castille-La Mancha (SESCAM), Spain. We performed the analysis using big data and artificial intelligence via Savana® Manager version 3.0.</p><p><strong>Results: </strong>During the study period, 103 667 patients were diagnosed with and treated for asthma at different care levels. The search was restricted to patients aged 10 to 90 years (mean age, 43.5 [95%CI, 43.4-43.7] years). Of these, 59.8% were women. SCs were taken for treatment of asthma by 58 745 patients at some point during the study period. These patients were older, with a higher prevalence of hypertension, dyslipidemia, diabetes, obesity, depression, and hiatus hernia. SCs are used frequently in the general population with asthma (31.4% in 2015 and 39.6% in 2019). SCs were prescribed mainly in primary care (59%), allergy (13%), and pulmonology (20%). The frequency of prescription of SCs had a direct impact on the main associated adverse effects.</p><p><strong>Conclusion: </strong>In clinical practice, SCs are frequently prescribed to patients with asthma, especially in primary care. Use of SCs is associated with a greater number of adverse events. It is necessary to implement measures to reduce prescription of SCs to patients with asthma, especially in primary care.</p>","PeriodicalId":50173,"journal":{"name":"Journal of Investigational Allergology and Clinical Immunology","volume":" ","pages":"30-38"},"PeriodicalIF":6.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10753210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Heterogeneity in Allergy to Mollusks: A Clinical-Immunological Study in a Population From the North of Spain. 软体动物过敏的异质性:西班牙北部人群的临床免疫学研究。
IF 6.1 3区 医学 Q1 ALLERGY Pub Date : 2024-10-01 Epub Date: 2017-01-03 DOI: 10.18176/jiaci.0137
J Azofra, S Echechipía, B Irazábal, D Muñoz, N Bernedo, B E García, G Gastaminza, M J Goikoetxea, A Joral, E Lasa, P Gamboa, C Díaz, A Beristain, D Quiñones, G Bernaola, M A Echenagusia, I Liarte, E García, J Cuesta, M D Martínez, M Velasco, N Longo, C Pastor-Vargas

Background and objective: Allergy to mollusks has been the focus of fewer studies than allergy to crustaceans. Furthermore, allergy to mollusks is less well characterized. Objectives: To describe the clinical characteristics of mollusk-allergic patients, to identify the responsible allergens, and to assess cross-reactivity.

Methods: We performed a prospective multicenter study including 45 patients with mollusk allergy, which was diagnosed based on a suggestive clinical history and a positive skin test result with the agent involved. Fractions were identified using SDS-PAGE and immunoblotting. The proteins responsible were subsequently identified using mass spectrometry. ELISA inhibition studies were performed with mollusks, dust mites, and crustaceans.

Results: We found that 25 patients (55%) were allergic to cephalopods, 14 (31%) to bivalves, and 11 (24%) to gastropods. Limpet was the third most frequent cause of allergy (15% of cases). In 31 patients (69%), the manifestation was systemic; 10 (22%) exhibited oral allergy syndrome, and 7 (15%) experienced contact urticaria. Most major allergens were found between 27 kDa and 47 kDa. ELISA inhibition assays revealed a high degree of inhibition of cephalopods and bivalves from all the groups of mollusks, mites, and crustaceans. Mass spectrometry identified tropomyosin, actin, and myosin as the major allergens.

Conclusions: Cephalopods, especially squid, are the mollusks that most frequently trigger allergic symptoms. The very frequent occurrence of allergy to limpets is striking, given their low consumption in our area. It is worth highlighting the heterogeneity observed, exemplified by the gastropods. Tropomyosin appears to be responsible for the high cross-reactivity found between mollusks, mites, and crustaceans. Three new mollusk allergens were also identified, namely, actin, enolase, and a putative C1q domain-containing protein.

背景:与甲壳类动物过敏相比,对软体动物过敏的研究较少。此外,对软体动物过敏的特征较少。目的:描述软体动物过敏患者的临床特征,确定致敏原,并评估交叉反应性。方法:我们进行了一项前瞻性多中心研究,包括45例软体动物过敏患者,根据提示的临床病史和相关药物的阳性皮肤试验结果进行诊断。采用SDS-PAGE和免疫印迹法对各组分进行鉴定。随后使用质谱法鉴定了负责的蛋白质。ELISA对软体动物、尘螨和甲壳类动物进行了抑制研究。结果:25例(55%)对头足类过敏,14例(31%)对双壳类过敏,11例(24%)对腹足类过敏。帽贝是第三大最常见的过敏原因(15%的病例)。31例(69%)患者表现为全身性;10例(22%)出现口腔过敏综合征,7例(15%)出现接触性荨麻疹。大多数主要过敏原在27 kDa和47 kDa之间。酶联免疫吸附试验显示,对软体动物、螨类和甲壳类的头足类和双壳类均有高度的抑制作用。质谱法鉴定原肌凝蛋白、肌动蛋白和肌凝蛋白为主要的过敏原。结论:头足类动物,尤其是鱿鱼,是最常引发过敏症状的软体动物。鉴于帽贝在我们地区的低消费量,对帽贝过敏的频繁发生令人吃惊。值得强调的是观察到的异质性,腹足类动物就是一个例子。原肌球蛋白似乎是软体动物、螨虫和甲壳类动物之间高交叉反应的原因。同时还鉴定出三种新的软体动物过敏原,即肌动蛋白、烯醇化酶和一种假定的C1q结构域蛋白。
{"title":"Heterogeneity in Allergy to Mollusks: A Clinical-Immunological Study in a Population From the North of Spain.","authors":"J Azofra, S Echechipía, B Irazábal, D Muñoz, N Bernedo, B E García, G Gastaminza, M J Goikoetxea, A Joral, E Lasa, P Gamboa, C Díaz, A Beristain, D Quiñones, G Bernaola, M A Echenagusia, I Liarte, E García, J Cuesta, M D Martínez, M Velasco, N Longo, C Pastor-Vargas","doi":"10.18176/jiaci.0137","DOIUrl":"10.18176/jiaci.0137","url":null,"abstract":"<p><strong>Background and objective: </strong>Allergy to mollusks has been the focus of fewer studies than allergy to crustaceans. Furthermore, allergy to mollusks is less well characterized. Objectives: To describe the clinical characteristics of mollusk-allergic patients, to identify the responsible allergens, and to assess cross-reactivity.</p><p><strong>Methods: </strong>We performed a prospective multicenter study including 45 patients with mollusk allergy, which was diagnosed based on a suggestive clinical history and a positive skin test result with the agent involved. Fractions were identified using SDS-PAGE and immunoblotting. The proteins responsible were subsequently identified using mass spectrometry. ELISA inhibition studies were performed with mollusks, dust mites, and crustaceans.</p><p><strong>Results: </strong>We found that 25 patients (55%) were allergic to cephalopods, 14 (31%) to bivalves, and 11 (24%) to gastropods. Limpet was the third most frequent cause of allergy (15% of cases). In 31 patients (69%), the manifestation was systemic; 10 (22%) exhibited oral allergy syndrome, and 7 (15%) experienced contact urticaria. Most major allergens were found between 27 kDa and 47 kDa. ELISA inhibition assays revealed a high degree of inhibition of cephalopods and bivalves from all the groups of mollusks, mites, and crustaceans. Mass spectrometry identified tropomyosin, actin, and myosin as the major allergens.</p><p><strong>Conclusions: </strong>Cephalopods, especially squid, are the mollusks that most frequently trigger allergic symptoms. The very frequent occurrence of allergy to limpets is striking, given their low consumption in our area. It is worth highlighting the heterogeneity observed, exemplified by the gastropods. Tropomyosin appears to be responsible for the high cross-reactivity found between mollusks, mites, and crustaceans. Three new mollusk allergens were also identified, namely, actin, enolase, and a putative C1q domain-containing protein.</p>","PeriodicalId":50173,"journal":{"name":"Journal of Investigational Allergology and Clinical Immunology","volume":"1 1","pages":"252-260"},"PeriodicalIF":6.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42619489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nonmandatory Labeled Legumes Are an Emergent Safety Concern: An Illustrative Case Report. 非强制性标签豆类食品是一个紧迫的安全问题:说明性案例报告。
IF 6.1 3区 医学 Q1 ALLERGY Pub Date : 2024-09-25 DOI: 10.18176/jiaci.1020
R N Vera-Berrios, L Uriarte Vega, G Marco-Martín, M Fernández-Rivas
{"title":"Nonmandatory Labeled Legumes Are an Emergent Safety Concern: An Illustrative Case Report.","authors":"R N Vera-Berrios, L Uriarte Vega, G Marco-Martín, M Fernández-Rivas","doi":"10.18176/jiaci.1020","DOIUrl":"https://doi.org/10.18176/jiaci.1020","url":null,"abstract":"","PeriodicalId":50173,"journal":{"name":"Journal of Investigational Allergology and Clinical Immunology","volume":" ","pages":"0"},"PeriodicalIF":6.1,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142331424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Occupational Asthma Caused by Exposure to Alumina. 接触氧化铝导致的职业性哮喘。
IF 6.1 3区 医学 Q1 ALLERGY Pub Date : 2024-07-29 Epub Date: 2024-02-21 DOI: 10.18176/jiaci.0974
M F Pilia, D Espejo, D Soler, X Muñoz
{"title":"Occupational Asthma Caused by Exposure to Alumina.","authors":"M F Pilia, D Espejo, D Soler, X Muñoz","doi":"10.18176/jiaci.0974","DOIUrl":"10.18176/jiaci.0974","url":null,"abstract":"","PeriodicalId":50173,"journal":{"name":"Journal of Investigational Allergology and Clinical Immunology","volume":" ","pages":"270-272"},"PeriodicalIF":6.1,"publicationDate":"2024-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139913940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Real-life Experience of Subcutaneous Plasma Derived C1-Inhibitor as Long-term Prophylaxis in HAE-C1INH. 皮下注射(SC)血浆衍生 C1 抑制剂(pdC1INH)作为 HAE-C1INH 长期预防(LTP)的实际经验。
IF 6.1 3区 医学 Q1 ALLERGY Pub Date : 2024-07-29 Epub Date: 2023-12-22 DOI: 10.18176/jiaci.0977
A Entrala, D Loli-Ausejo, I Losantos, R Cabañas, T Caballero
{"title":"Real-life Experience of Subcutaneous Plasma Derived C1-Inhibitor as Long-term Prophylaxis in HAE-C1INH.","authors":"A Entrala, D Loli-Ausejo, I Losantos, R Cabañas, T Caballero","doi":"10.18176/jiaci.0977","DOIUrl":"10.18176/jiaci.0977","url":null,"abstract":"","PeriodicalId":50173,"journal":{"name":"Journal of Investigational Allergology and Clinical Immunology","volume":" ","pages":"261-263"},"PeriodicalIF":6.1,"publicationDate":"2024-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138832701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Successful Subcutaneous Desensitization to Certolizumab Pegol. certolizumab皮下脱敏成功。
IF 6.1 3区 医学 Q1 ALLERGY Pub Date : 2024-07-29 Epub Date: 2024-01-26 DOI: 10.18176/jiaci.0981
M J Peñalver, S Bautista-Villanueva, R Barranco, J F Crespo, R Mielgo
{"title":"Successful Subcutaneous Desensitization to Certolizumab Pegol.","authors":"M J Peñalver, S Bautista-Villanueva, R Barranco, J F Crespo, R Mielgo","doi":"10.18176/jiaci.0981","DOIUrl":"10.18176/jiaci.0981","url":null,"abstract":"","PeriodicalId":50173,"journal":{"name":"Journal of Investigational Allergology and Clinical Immunology","volume":" ","pages":"272-274"},"PeriodicalIF":6.1,"publicationDate":"2024-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139565277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevalence of Atopic Dermatitis in the Adult Population of Catalonia, Spain: A Large-Scale, Retrospective, Population-Based Study. 加泰罗尼亚(西班牙)成人特应性皮炎患病率:一项基于人口的大规模回顾性研究。
IF 6.1 3区 医学 Q1 ALLERGY Pub Date : 2024-07-29 Epub Date: 2023-02-23 DOI: 10.18176/jiaci.0899
T Mora, I Sánchez-Collado, J Mullol, R Muñoz-Cano, P Ribó, A Valero

Background: Studies on the prevalence of atopic dermatitis (AD) in adults in general populations are scarce worldwide. We performed a retrospective population-based observational cohort study of 537 098 adult patients diagnosed with AD in Catalonia, Spain, a larger population than in previous studies. Objectives: To study the prevalence of AD by age, sex, disease severity, multimorbidity, serum total immunoglobin E (tIgE), and appropriate medical treatment (AMT) for the population of Catalonia.

Methods: The study population comprised adult individuals (≥18 years) diagnosed with AD according to medical records at different health care levels (primary, hospital, emergency) in the Catalan Health System. Statistical analyses were conducted to evaluate sociodemographic characteristics, prevalence, multimorbidity, serum tIgE, and AMT.

Results: The prevalence of AD in the adult Catalan population was 8.7%, being higher for nonsevere disease (8.5%) than for severe disease (0.2%) and in females (10.1%) than in males (7.3%). Topical corticosteroids were the most prescribed drug (66.5%), and treatment was prescribed more frequently in severe AD patients, especially systemic corticosteroids (63.8%) and immunosuppressants (60.7%). More than half of severe AD patients (52.2%) had serum tIgE ≥100 kU/L, and higher values were observed for those with multimorbidity. The most frequent comorbid respiratory diseases were acute bronchitis (13.7%), allergic rhinitis (12.1%), and asthma (8.6%).

Conclusions: We provide new and robust evidence of the prevalence of AD and related characteristics in adults using a large-scale population-based study and a more significant cohort of individuals.

背景和目的:在全球范围内,有关特应性皮炎(AD)在普通人群中的成人患病率的研究很少。我们对加泰罗尼亚(西班牙)537,098 名确诊为特应性皮炎的成年患者进行了一项基于人群的回顾性队列观察研究,该研究的人群规模大于以往的研究。目的是研究按年龄、性别、疾病严重程度、多病症、血清总免疫球蛋白 E (tIgE) 和接受适当治疗 (AMT) 划分的加泰罗尼亚人群的 AD 患病率:方法:纳入加泰罗尼亚卫生系统(CHS)不同医疗保健级别(初级、医院、急诊)的医疗记录中确诊为注意力缺失症的成年人(≥18 岁)。对社会人口学特征、发病率、多病症、血清 tIgE 和 AMT 进行了统计分析:加泰罗尼亚成年人口中确诊的注意力缺失症总发病率为 8.7%,非重度人群(8.5%)高于重度人群(0.2%),女性(10.1%)高于男性(7.3%)。外用皮质类固醇激素是最常用的处方药(66.5%),在严重AD患者中,所有处方药的使用率都较高,尤其是全身性皮质类固醇激素(63.8%)和免疫抑制剂(60.7%)。半数以上(52.2%)的重症AD患者报告血清tIgE≥100 KU/L,患有多种疾病的患者血清tIgE值更高。急性支气管炎(13.7%)、过敏性鼻炎(12.1%)和哮喘(8.6%)是最常见的合并呼吸系统疾病:我们的研究通过大规模的人群研究和更重要的个体队列,为成人注意力缺失症的患病率和相关特征提供了新的有力证据。
{"title":"Prevalence of Atopic Dermatitis in the Adult Population of Catalonia, Spain: A Large-Scale, Retrospective, Population-Based Study.","authors":"T Mora, I Sánchez-Collado, J Mullol, R Muñoz-Cano, P Ribó, A Valero","doi":"10.18176/jiaci.0899","DOIUrl":"10.18176/jiaci.0899","url":null,"abstract":"<p><strong>Background: </strong>Studies on the prevalence of atopic dermatitis (AD) in adults in general populations are scarce worldwide. We performed a retrospective population-based observational cohort study of 537 098 adult patients diagnosed with AD in Catalonia, Spain, a larger population than in previous studies. Objectives: To study the prevalence of AD by age, sex, disease severity, multimorbidity, serum total immunoglobin E (tIgE), and appropriate medical treatment (AMT) for the population of Catalonia.</p><p><strong>Methods: </strong>The study population comprised adult individuals (≥18 years) diagnosed with AD according to medical records at different health care levels (primary, hospital, emergency) in the Catalan Health System. Statistical analyses were conducted to evaluate sociodemographic characteristics, prevalence, multimorbidity, serum tIgE, and AMT.</p><p><strong>Results: </strong>The prevalence of AD in the adult Catalan population was 8.7%, being higher for nonsevere disease (8.5%) than for severe disease (0.2%) and in females (10.1%) than in males (7.3%). Topical corticosteroids were the most prescribed drug (66.5%), and treatment was prescribed more frequently in severe AD patients, especially systemic corticosteroids (63.8%) and immunosuppressants (60.7%). More than half of severe AD patients (52.2%) had serum tIgE ≥100 kU/L, and higher values were observed for those with multimorbidity. The most frequent comorbid respiratory diseases were acute bronchitis (13.7%), allergic rhinitis (12.1%), and asthma (8.6%).</p><p><strong>Conclusions: </strong>We provide new and robust evidence of the prevalence of AD and related characteristics in adults using a large-scale population-based study and a more significant cohort of individuals.</p>","PeriodicalId":50173,"journal":{"name":"Journal of Investigational Allergology and Clinical Immunology","volume":" ","pages":"225-232"},"PeriodicalIF":6.1,"publicationDate":"2024-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9307308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Use of Triple Therapy in Asthma: The GEMAFORUM V Task Force. 三联疗法在哮喘中的应用。GEMA-FORUM V 特别工作组。
IF 6.1 3区 医学 Q1 ALLERGY Pub Date : 2024-07-29 Epub Date: 2024-02-09 DOI: 10.18176/jiaci.0975
V Plaza, J A Trigueros, J A Carretero, I Ojanguren Arranz, J M Vega Chicote, C Almonacid Sánchez, J Bartra Tomás, C Cisneros Serrano, L Domínguez Juncal, J Domínguez-Ortega, J Figueroa Rivero, J G Soto Campos, E Macías Fernández, S Martínez, J Montoro Lacomba, S Quirce
{"title":"Use of Triple Therapy in Asthma: The GEMAFORUM V Task Force.","authors":"V Plaza, J A Trigueros, J A Carretero, I Ojanguren Arranz, J M Vega Chicote, C Almonacid Sánchez, J Bartra Tomás, C Cisneros Serrano, L Domínguez Juncal, J Domínguez-Ortega, J Figueroa Rivero, J G Soto Campos, E Macías Fernández, S Martínez, J Montoro Lacomba, S Quirce","doi":"10.18176/jiaci.0975","DOIUrl":"10.18176/jiaci.0975","url":null,"abstract":"","PeriodicalId":50173,"journal":{"name":"Journal of Investigational Allergology and Clinical Immunology","volume":" ","pages":"257-260"},"PeriodicalIF":6.1,"publicationDate":"2024-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139708388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Off-label Use of Mepolizumab: A Potential Therapeutic Option for Eosinophilic Cystitis. 美妥珠单抗的标签外使用:嗜酸性细胞性膀胱炎的潜在治疗方案
IF 6.1 3区 医学 Q1 ALLERGY Pub Date : 2024-07-29 Epub Date: 2023-12-12 DOI: 10.18176/jiaci.0973
G Wang, N Zhuo, Z Liu
{"title":"Off-label Use of Mepolizumab: A Potential Therapeutic Option for Eosinophilic Cystitis.","authors":"G Wang, N Zhuo, Z Liu","doi":"10.18176/jiaci.0973","DOIUrl":"10.18176/jiaci.0973","url":null,"abstract":"","PeriodicalId":50173,"journal":{"name":"Journal of Investigational Allergology and Clinical Immunology","volume":" ","pages":"277-278"},"PeriodicalIF":6.1,"publicationDate":"2024-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138811925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Investigational Allergology and Clinical Immunology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1